The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2015

Filed:

Jul. 07, 2011
Applicants:

Steven L. Mcknight, Dallas, TX (US);

Andrew A. Pieper, Plano, TX (US);

Joseph M. Ready, Carrollton, TX (US);

Jef K. DE Brabander, Flower Mound, TX (US);

Inventors:

Steven L. McKnight, Dallas, TX (US);

Andrew A. Pieper, Plano, TX (US);

Joseph M. Ready, Carrollton, TX (US);

Jef K. De Brabander, Flower Mound, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/82 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/4045 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/506 (2006.01); C07D 209/08 (2006.01); C07D 209/86 (2006.01); C07D 209/88 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/06 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01); C07F 5/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/404 (2013.01); A61K 31/403 (2013.01); A61K 31/4045 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); C07D 209/08 (2013.01); C07D 209/82 (2013.01); C07D 209/86 (2013.01); C07D 209/88 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/06 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01); C07F 5/022 (2013.01);
Abstract

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.


Find Patent Forward Citations

Loading…